FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130941330> ?p ?o ?g. }

• W2130941330 endingPage "47" @default.
• W2130941330 startingPage "39" @default.
• W2130941330 abstract "Octreotide, a somatostatin analogue, has been shown to prevent angiogenesis in diverse in vitro models. We evaluated its effect on retinal neovascularization in vivo, using a neonatal rat retinopathy model.We used, on alternating days, hypoxia (10% O2) and hyperoxia (50% O2) during the first 14 days of neonatal rats, to induce retinal neovascularization. Half of the rats were injected subcutaneously with octreotide 0.7 microg/g BW twice daily. At day 18 the eyes were evaluated for the presence of epiretinal and vitreal hemorrhage, neovascularization and epiretinal proliferation. Octreotide pharmacokinetics and its effect on serum growth hormone (GH) and insulin-like growth factor I (IGF-I) were examined in 28 rats.Serum octreotide levels were 667 microg/l two hours after injection, 26.4 microg/l after nine hours and 3.2 microg/l after 14 hours. GH levels were decreased by 40% (p = 0.002) two hours after injection but thereafter returned to baseline. IGF-I levels were unchanged two hours after injection and were elevated by 26% 14 hours after injection (p = 0.02). Epiretinal membranes were highly associated with epiretinal hemorrhages (p < 0.001), while retinal neovascularization was notably associated with vitreal hemorrhages (p < 0.001).Twice-daily injections of octreotide failed to produce sustained decrease in serum GH, but produced rebound elevation of serum IGF-I. Accordingly, no statistically significant effect of injections on retinal pathology was noted. This finding, however, does not contradict our assumption that GH suppression may decrease the severity of retinopathy." @default.
• W2130941330 created "2016-06-24" @default.
• W2130941330 creator A5005233299 @default.
• W2130941330 creator A5008289229 @default.
• W2130941330 creator A5041201756 @default.
• W2130941330 creator A5066308399 @default.
• W2130941330 creator A5073517018 @default.
• W2130941330 creator A5081200496 @default.
• W2130941330 creator A5081265839 @default.
• W2130941330 creator A5084608581 @default.
• W2130941330 date "2000-01-01" @default.
• W2130941330 modified "2023-09-26" @default.
• W2130941330 title "Octreotide, a Somatostatin Analogue, Fails to Inhibit Hypoxia-induced Retinal Neovascularization in the Neonatal Rat" @default.
• W2130941330 cites W1019753257 @default.
• W2130941330 cites W123207628 @default.
• W2130941330 cites W1565678084 @default.
• W2130941330 cites W1991599584 @default.
• W2130941330 cites W2006611896 @default.
• W2130941330 cites W2014793666 @default.
• W2130941330 cites W2015852353 @default.
• W2130941330 cites W2038198672 @default.
• W2130941330 cites W2052528095 @default.
• W2130941330 cites W2078731699 @default.
• W2130941330 cites W2079849586 @default.
• W2130941330 cites W2087438017 @default.
• W2130941330 cites W2088255586 @default.
• W2130941330 cites W2092237858 @default.
• W2130941330 cites W2119762602 @default.
• W2130941330 cites W2125632759 @default.
• W2130941330 cites W2128376618 @default.
• W2130941330 cites W2151397963 @default.
• W2130941330 cites W2169047506 @default.
• W2130941330 cites W2327866243 @default.
• W2130941330 cites W2409045744 @default.
• W2130941330 cites W2415635857 @default.
• W2130941330 cites W37034640 @default.
• W2130941330 cites W48863528 @default.
• W2130941330 cites W2014450888 @default.
• W2130941330 doi "https://doi.org/10.1155/edr.2000.39" @default.
• W2130941330 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2477751" @default.
• W2130941330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11469389" @default.
• W2130941330 hasPublicationYear "2000" @default.
• W2130941330 type Work @default.
• W2130941330 sameAs 2130941330 @default.
• W2130941330 citedByCount "13" @default.
• W2130941330 countsByYear W21309413302012 @default.
• W2130941330 countsByYear W21309413302015 @default.
• W2130941330 crossrefType "journal-article" @default.
• W2130941330 hasAuthorship W2130941330A5005233299 @default.
• W2130941330 hasAuthorship W2130941330A5008289229 @default.
• W2130941330 hasAuthorship W2130941330A5041201756 @default.
• W2130941330 hasAuthorship W2130941330A5066308399 @default.
• W2130941330 hasAuthorship W2130941330A5073517018 @default.
• W2130941330 hasAuthorship W2130941330A5081200496 @default.
• W2130941330 hasAuthorship W2130941330A5081265839 @default.
• W2130941330 hasAuthorship W2130941330A5084608581 @default.
• W2130941330 hasBestOaLocation W21309413301 @default.
• W2130941330 hasConcept C118487528 @default.
• W2130941330 hasConcept C126322002 @default.
• W2130941330 hasConcept C134018914 @default.
• W2130941330 hasConcept C150903083 @default.
• W2130941330 hasConcept C178790620 @default.
• W2130941330 hasConcept C185592680 @default.
• W2130941330 hasConcept C207001950 @default.
• W2130941330 hasConcept C2776297358 @default.
• W2130941330 hasConcept C2777714996 @default.
• W2130941330 hasConcept C2778271429 @default.
• W2130941330 hasConcept C2778313320 @default.
• W2130941330 hasConcept C2780394083 @default.
• W2130941330 hasConcept C2780672939 @default.
• W2130941330 hasConcept C2780827179 @default.
• W2130941330 hasConcept C2781025020 @default.
• W2130941330 hasConcept C540031477 @default.
• W2130941330 hasConcept C555293320 @default.
• W2130941330 hasConcept C71924100 @default.
• W2130941330 hasConcept C7836513 @default.
• W2130941330 hasConcept C86803240 @default.
• W2130941330 hasConceptScore W2130941330C118487528 @default.
• W2130941330 hasConceptScore W2130941330C126322002 @default.
• W2130941330 hasConceptScore W2130941330C134018914 @default.
• W2130941330 hasConceptScore W2130941330C150903083 @default.
• W2130941330 hasConceptScore W2130941330C178790620 @default.
• W2130941330 hasConceptScore W2130941330C185592680 @default.
• W2130941330 hasConceptScore W2130941330C207001950 @default.
• W2130941330 hasConceptScore W2130941330C2776297358 @default.
• W2130941330 hasConceptScore W2130941330C2777714996 @default.
• W2130941330 hasConceptScore W2130941330C2778271429 @default.
• W2130941330 hasConceptScore W2130941330C2778313320 @default.
• W2130941330 hasConceptScore W2130941330C2780394083 @default.
• W2130941330 hasConceptScore W2130941330C2780672939 @default.
• W2130941330 hasConceptScore W2130941330C2780827179 @default.
• W2130941330 hasConceptScore W2130941330C2781025020 @default.
• W2130941330 hasConceptScore W2130941330C540031477 @default.
• W2130941330 hasConceptScore W2130941330C555293320 @default.
• W2130941330 hasConceptScore W2130941330C71924100 @default.
• W2130941330 hasConceptScore W2130941330C7836513 @default.
• W2130941330 hasConceptScore W2130941330C86803240 @default.
• W2130941330 hasIssue "1" @default.

• next